Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study (Journal article)

Fountzilas, G./ Nicolaides, C./ Aravantinos, G./ Skarlos, D./ Kosmidis, P./ Papakostas, P./ Stathopoulos, G. P./ Kontostolis, E./ Bafaloukos, D./ Pavlidis, N.

Forty-one patients with operable breast cancer and >/=10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A total of 240 cycles were administered, all of them at full dose and 19 (8%) with a delay. Thirty-eight (93%) patients completed the treatment according to the protocol. The relative dose intensity of epirubicin was 0.99. Grade 3 toxicities included anemia (3%), nausea and vomiting (5%) and alopecia (71%). After a median follow-up of 40 months, 16 (39%) patients were free of relapse. In conclusion, the present study has shown that the administration of dose-dense chemotherapy with epirubicin is feasible in the adjuvant setting with minimal toxicity.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Antibiotics, Antineoplastic/*therapeutic use,Breast Neoplasms/*drug therapy/*surgery,Combined Modality Therapy,Dose-Response Relationship, Drug,Drug Administration Schedule,Epirubicin/*therapeutic use,Feasibility Studies,Female,Follow-Up Studies,Granulocyte Colony-Stimulating Factor/therapeutic use,Humans,Lymphatic Metastasis,Middle Aged
ISSN: 0030-2414
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.